Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2023 8
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Ivosidenib in acute myeloid leukemia.
Bruzzese A, Labanca C, Martino EA, Mendicino F, Lucia E, Olivito V, Neri A, Imovilli A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: labanca c. Expert Opin Pharmacother. 2023 Sep-Dec;24(18):2093-2100. doi: 10.1080/14656566.2023.2272659. Epub 2024 Jan 5. Expert Opin Pharmacother. 2023. PMID: 37874005 Review.
Momelotinib in myelofibrosis.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Zimbo A, Fragliasso V, Neri A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: labanca c. Expert Opin Pharmacother. 2024 Apr 18:1-8. doi: 10.1080/14656566.2024.2343780. Online ahead of print. Expert Opin Pharmacother. 2024. PMID: 38623844 Review.
Belantamab mafodotin in multiple myeloma.
Martino EA, Bruzzese A, Iaccino E, Labanca C, Mendicino F, Mimmi S, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M. Martino EA, et al. Among authors: labanca c. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1043-1047. doi: 10.1080/14712598.2023.2218543. Epub 2023 May 27. Expert Opin Biol Ther. 2023. PMID: 37227998 No abstract available.
Teclistamab-cqyv in multiple myeloma.
Martino EA, Bruzzese A, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M. Martino EA, et al. Among authors: labanca c. Eur J Haematol. 2024 Mar;112(3):320-327. doi: 10.1111/ejh.14121. Epub 2023 Oct 17. Eur J Haematol. 2024. PMID: 37848191 Review.
Tagraxofusp in myeloid malignancies.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Imovilli A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: labanca c. Hematol Oncol. 2024 Jan;42(1):e3234. doi: 10.1002/hon.3234. Epub 2023 Oct 17. Hematol Oncol. 2024. PMID: 37846131 Review.
Selinexor in multiple myeloma.
Martino EA, Vigna E, Bruzzese A, Labanca C, Mendicino F, Lucia E, Olivito V, Zimbo A, Torricelli F, Neri A, Morabito F, Gentile M. Martino EA, et al. Among authors: labanca c. Expert Opin Pharmacother. 2024 Mar 25:1-14. doi: 10.1080/14656566.2024.2333376. Online ahead of print. Expert Opin Pharmacother. 2024. PMID: 38503547 Review.
Zanubrutinib for the treatment of chronic lymphocytic leukemia.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: labanca c. Expert Opin Pharmacother. 2023 Sep-Dec;24(13):1409-1413. doi: 10.1080/14656566.2023.2229734. Epub 2023 Jun 26. Expert Opin Pharmacother. 2023. PMID: 37350553 No abstract available.
Glasdegib for the treatment of acute myeloid leukemia.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Fimognari F, Neri A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: labanca c. Expert Opin Pharmacother. 2023 Sep-Dec;24(14):1537-1543. doi: 10.1080/14656566.2023.2232301. Epub 2023 Jul 3. Expert Opin Pharmacother. 2023. PMID: 37392098
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: labanca c. Expert Opin Investig Drugs. 2024 Feb;33(2):73-77. doi: 10.1080/13543784.2024.2309873. Epub 2024 Jan 26. Expert Opin Investig Drugs. 2024. PMID: 38264792 No abstract available.
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis.
Staropoli N, Ciliberto D, Luciano F, Napoli C, Costa M, Rossini G, Arbitrio M, Labanca C, Riillo C, Del Giudice T, Crispino A, Salvino A, Galvano A, Russo A, Tassone P, Tagliaferri P. Staropoli N, et al. Among authors: labanca c. Crit Rev Oncol Hematol. 2024 Jan;193:104229. doi: 10.1016/j.critrevonc.2023.104229. Epub 2023 Dec 7. Crit Rev Oncol Hematol. 2024. PMID: 38065404 Free article. Review.
14 results